XML 11 R2.htm IDEA: XBRL DOCUMENT v3.23.1
Condensed Consolidated Balance Sheets (Unaudited) - USD ($)
Mar. 31, 2023
Dec. 31, 2022
Current assets    
Cash $ 4,362,757 $ 7,034,434
Accounts receivable, net 411,104 538,587
Inventory, net 1,480,755 1,586,297
Prepaid expenses and other current assets 1,283,358 1,661,220
Total current assets 7,537,974 10,820,538
Restricted cash 5,586 5,690
Right-of-use assets 1,364,901 1,422,538
Property and equipment, net 522,408 345,087
Intangible assets, net 5,839,330 5,845,702
Goodwill 625,602 625,602
Other assets 18,334 18,334
Total Assets 15,914,135 19,083,491
Current liabilities    
Accounts payable 899,948 857,311
Accrued vacation 353,557 467,948
Accrued expenses and other current liabilities 1,893,733 1,511,856
R&D grant liability 634,330 780,682
Deferred revenue, current portion 112,902 116,161
Operating lease liability, current portion 248,809 240,645
Short term debt-related party 958,952 950,722
Warrant liabilities 400,800 788,100
Warrant liabilities - related party 2,183,174 2,834,547
Convertible debt - related party 558,238 60,197
Total current liabilities 8,244,442 8,608,170
Operating lease liability, net of current portion 1,236,024 1,301,919
Deferred revenue, net of current portion 40,712 49,056
Deferred tax liability 192,587 357,757
Total liabilities 9,713,766 10,316,902
Commitments and Contingencies (Note 13)
Qualigen Therapeutics, Inc. stockholders’ equity:    
Common stock, $0.001 par value; 225,000,000 shares authorized; 5,052,463 and 4,210,737 shares issued and outstanding as of March 31, 2023 and December 31, 2022, respectively 42,952 42,110
Additional paid-in capital 111,887,447 110,528,050
Accumulated other comprehensive income 170,444 50,721
Accumulated deficit (107,231,393) (103,385,172)
Total Qualigen Therapeutics, Inc. stockholders’ equity 4,869,450 7,235,709
Noncontrolling interest 1,330,919 1,530,881
Total Stockholders’ Equity 6,200,369 8,766,590
Total Liabilities & Stockholders’ Equity $ 15,914,135 $ 19,083,491